Seattle Genetics (SGEN) Highlights Additional Analyses from Phase 3 ECHELON-1 Clinical Trial of ADCETRIS in Newly Diagnosed Advanced HL at ASCO
June 4, 2018 9:09 AM
Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted data from the phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) in ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
